

Yulia A Nevzorova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7846610/publications.pdf>

Version: 2024-02-01

42
papers

1,465
citations

331259

21
h-index

329751

37
g-index

42
all docs

42
docs citations

42
times ranked

2589
citing authors

#	ARTICLE	IF	CITATIONS
1	Animal models for liver disease – A practical approach for translational research. <i>Journal of Hepatology</i> , 2020, 73, 423-440.	1.8	139
2	Alcoholic liver disease: Utility of animal models. <i>World Journal of Gastroenterology</i> , 2018, 24, 5063-5075.	1.4	101
3	Combined Activities of JNK1 and JNK2 in Hepatocytes Protect Against Toxic Liver Injury. <i>Gastroenterology</i> , 2016, 150, 968-981.	0.6	82
4	The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF- β 2 signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 902-914.	1.9	81
5	<p>Guidelines and Considerations for Metabolic Tolerance Tests in Mice</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 439-450.	1.1	81
6	p38 β is essential for cell cycle progression and liver tumorigenesis. <i>Nature</i> , 2019, 568, 557-560.	13.7	72
7	Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9282-9287.	3.3	68
8	Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 1765-1775.	1.8	67
9	c-MYC – Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. <i>Genes</i> , 2017, 8, 123.	1.0	59
10	Aberrant Cell Cycle Progression and Endoreplication in Regenerating Livers of Mice That Lack a Single E-Type Cyclin. <i>Gastroenterology</i> , 2009, 137, 691-703.e6.	0.6	56
11	The Lieber – DeCarli Diet – A Flagship Model for Experimental Alcoholic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1828-1840.	1.4	55
12	Cyclin E1 controls proliferation of hepatic stellate cells and is essential for liver fibrogenesis in mice. <i>Hepatology</i> , 2012, 56, 1140-1149.	3.6	50
13	Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis. <i>Gut</i> , 2014, 63, 1159-1172.	6.1	47
14	Partial hepatectomy in mice. <i>Laboratory Animals</i> , 2015, 49, 81-88.	0.5	45
15	Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. <i>Hepatology</i> , 2014, 59, 651-660.	3.6	41
16	Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame. <i>Cancers</i> , 2017, 9, 130.	1.7	38
17	Inhibition of Caspase-8 does not protect from alcohol-induced liver apoptosis but alleviates alcoholic hepatic steatosis in mice. <i>Cell Death and Disease</i> , 2017, 8, e3152-e3152.	2.7	34
18	TNFR1 determines progression of chronic liver injury in the IKK β /Nemo genetic model. <i>Cell Death and Differentiation</i> , 2013, 20, 1580-1592.	5.0	33

#	ARTICLE	IF	CITATIONS
19	Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease. <i>Journal of Hepatology</i> , 2016, 64, 628-640.	1.8	29
20	Loss of caspase-8 in hepatocytes accelerates the onset of liver regeneration in mice through premature nuclear factor kappa B activation. <i>Hepatology</i> , 2013, 58, 1779-1789.	3.6	28
21	Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. <i>Digestive and Liver Disease</i> , 2021, 53, 525-533.	0.4	27
22	Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. <i>Cell Death and Disease</i> , 2015, 6, e1667-e1667.	2.7	25
23	Fibrotic Events in the Progression of Cholestatic Liver Disease. <i>Cells</i> , 2021, 10, 1107.	1.8	24
24	The Space of Disse: The Liver Hub in Health and Disease. <i>Livers</i> , 2021, 1, 3-26.	0.8	23
25	Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes in vivo. <i>Hepatology</i> , 2006, 44, 164-173.	3.6	22
26	Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury. <i>Journal of Hepatology</i> , 2015, 62, 140-149.	1.8	20
27	Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma. <i>Hepatology Communications</i> , 2020, 4, 834-851.	2.0	17
28	Intestinal Epithelial Cell-Derived Extracellular Vesicles Modulate Hepatic Injury via the Gut-Liver Axis During Acute Alcohol Injury. <i>Frontiers in Pharmacology</i> , 2020, 11, 603771.	1.6	17
29	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	1.7	15
30	An Experimental DUAL Model of Advanced Liver Damage. <i>Hepatology Communications</i> , 2021, 5, 1051-1068.	2.0	11
31	Anti-tumorigenic and anti-angiogenic effects of natural conifer <i>Abies sibirica</i> terpenoids in vivo and in vitro. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 386-395.	2.5	10
32	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2027.	1.8	10
33	Bone marrow-derived c-jun N-terminal kinase-1 (JNK1) mediates liver regeneration. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 137-145.	1.8	9
34	Liver Fibrosis – From Mechanisms of Injury to Modulation of Disease. <i>Frontiers in Medicine</i> , 2021, 8, 814496.	1.2	9
35	Pharmacological Inhibition of Cyclin-Dependent Kinases Triggers Anti-Fibrotic Effects in Hepatic Stellate Cells In Vitro. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3267.	1.8	8
36	Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). <i>Biomedicines</i> , 2021, 9, 1289.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterology & Hepatology, 2022, 45, 724-734.	0.2	3
38	Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. Cancers, 2022, 14, 78.	1.7	3
39	Sh(i)pping signals protect against Stat3-driven liver cancer. Hepatology, 2012, 55, 322-324.	3.6	1
40	Regulation of Cell Cycle During Liver Regeneration. , 2015, , 153-166.		1
41	Liver Regeneration. , 2012, , 20-35.		0
42	THU-018-c-Jun N-terminal kinases act synergistically in hepatocytes to protect mice from cholestatic liver injury. Journal of Hepatology, 2019, 70, e168.	1.8	0